CANDIDIASIS

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。新生儿念珠菌病是一种致命性疾病，人们对此知之甚少。尽管可归因性死亡率为30%，但目前诊断新生儿念珠菌病的金标准(重复培养正常无菌体液)的敏感度为50%；而且还没有前瞻性研究来建立启动经验性治疗的指南。该方案将建立1,750名出生体重为1000克的婴儿的前瞻性队列，以评估三种新的诊断测试，并开发侵袭性念珠菌病的风险分层模型。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Neonatal candidiasis is a lethal disease that is poorly understood. Despite an attributable mortality of 30%, the current gold standard for the diagnosis of neonatal candidiasis (repeated culture of normally sterile body fluid) has a sensitivity of 50%; and there have been no prospective studies to establish guidelines for the initiation of empirical treatment. This protocol will establish a prospective cohort of 1,750 infants born <1000 grams birthweight in order to evaluate three new diagnostic tests and develop a risk stratification model for invasive candidiasis.